跳转至内容
Merck
CN

P0080

Sigma-Aldrich

普伦司特 半水合物

≥98% (HPLC), CysLT1 receptor antagonist, solid

别名:

8-[4(4-phenylbutoxy)benzoyl]amino-2-(5-tetrazolyl)-4-oxo-4H-1-benzopyran

登录查看公司和协议定价

选择尺寸

关于此项目

经验公式（希尔记法）:
C27H23N5O4 · 0.5 H2O
化学文摘社编号:
150821-03-7
分子量:
490.51
MDL编号:
MFCD24539454
UNSPSC代码:
51111800
PubChem化学物质编号:
329820009
NACRES:
NA.77

主要文件

查看所有文档
技术服务
需要帮助？我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助
技术服务
需要帮助？我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

产品名称

普伦司特 半水合物, ≥98% (HPLC), white, solid

质量水平

100

方案

≥98% (HPLC)

表单

solid

颜色

white

溶解性

DMSO: ≥10 mg/mL
H2O: insoluble

储存温度

−20°C

SMILES字符串

O.O=C(Nc1cccc2C(=O)C=C(Oc12)c3nnn[nH]3)c4ccc(OCCCCc5ccccc5)cc4.O=C(Nc6cccc7C(=O)C=C(Oc67)c8nnn[nH]8)c9ccc(OCCCCc%10ccccc%10)cc9

InChI

1S/2C27H23N5O4.H2O/c2*33-23-17-24(26-29-31-32-30-26)36-25-21(23)10-6-11-22(25)28-27(34)19-12-14-20(15-13-19)35-16-5-4-9-18-7-2-1-3-8-18;/h2*1-3,6-8,10-15,17H,4-5,9,16H2,(H,28,34)(H,29,30,31,32);1H2

InChI key

MSXTUBJFNBZPGC-UHFFFAOYSA-N

相关类别

生化/生理作用

Pranlukast is a subtype specific CysLT1 receptor antagonist.
Pranlukast is a subtype specific CysLT1 receptor antagonist. Leukotrienes are involved in the inflammation response and are divided into two main classes; leukotriene B4 and cysteinyl-substituted leukotrienes.

特点和优势

This compound is featured on the Leukotriene Receptors page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.

象形图

Exclamation mark
GHS07

警示用语：

Warning

危险分类

Acute Tox. 4 Oral - Aquatic Chronic 4 - Eye Irrit. 2 - Skin Irrit. 2 - STOT SE 3

靶器官

Respiratory system

储存分类代码

11 - Combustible Solids

WGK

WGK 3

闪点(°F)

Not applicable

闪点(°C)

Not applicable

个人防护装备

dust mask type N95 (US), Eyeshields, Gloves

法规信息

新产品
此项目有

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number
0000496313
0000496312
0000496313
0000496312
0000418346

没有发现合适的版本？

如果您需要特殊版本，可通过批号或批次号查找具体证书。

搜索COA

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

Inés Velázquez-Quesada et al.
Drug design, development and therapy, 14, 1799-1811 (2020-06-05)
Cancer stem cells (CSCs) drive the initiation, maintenance, and therapy response of breast tumors. CD49f is expressed in breast CSCs and functions in the maintenance of stemness. Thus, blockade of CD49f is a potential therapeutic approach for targeting breast CSCs.
Eun-Sol Ha et al.
Drug design, development and therapy, 9, 3257-3266 (2015-07-08)
The present study was carried out to develop an oral formulation of pranlukast hemihydrate with improved dissolution and oral bioavailability using a surface-modified microparticle. Based on solubility measurements, surface-modified pranlukast hemihydrate microparticles were manufactured using the spray-drying method with hydroxypropylmethyl

我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持